



GOVERNMENT WHIPS' OFFICE  
HOUSE OF LORDS  
LONDON SW1A 0PW

LORD YOUNG OF COOKHAM  
020 7219 3778

Telephone 020-7219 3131  
[www.lordswhips.org.uk](http://www.lordswhips.org.uk)  
[holgovernmentwhips@parliament.uk](mailto:holgovernmentwhips@parliament.uk)

22 July 2019

Thank you for your contribution in the recent Question for Short Debate on the G20 Summit on Monday 8 July. I am writing to address the concerns you raised on the issue of Anti-Microbial Resistance (AMR) and to provide you with an update on the UK's action, specifically on our work addressing the market failure in the development of antimicrobials.

You will be aware that in July NICE, NHS England & NHS Improvement formally launched a world-leading project to develop and test a new model for the evaluation and purchasing of antimicrobials in the UK. As part of the launch, they have called for companies to identify candidate products to be included at the topic selection stage. The launch also signals the start of a period of targeted engagement, in which we will seek input from a wide range of stakeholders, including industry, on the proposed models and topic selection process. We anticipate announcing the two products chosen for the project by the end of October, and their value assessment will take place through 2020.

As you know, the UK represents only a small part of the global market for these vital drugs and so for this to have the full effect, we need other countries to test similar models and other solutions in their own domestic markets. As part of our targeted engagement, we have established a stakeholder advisory group of national and international contacts who will be regularly updated on our project's developments and can act as global advocates to champion the approach and disseminate learning. We will also continue to showcase the project at international events and through our bilateral relationships with countries and other relevant organisations. We hope that this will provide the impetus for other countries to take practical steps to address the failure in their own markets and are, indeed, already generating a lot of interest in this work, including from the USA and Japan.


In parallel, the UK continues to concentrate its efforts in generating political momentum around market failure in multilateral fora, namely the G20 as the world's leading economic forum. Due to the hard work of our G20 Sherpa team and colleagues across government this year, the UK was successful in securing a tangible commitment to AMR and market incentives work in the Osaka Leaders' Declaration. We are following this up with the relevant organisations to ensure that words are turned into action. We are also attempting to agree similar ambitious text in the G20 Health Declaration, although we remain cautious, based on the discussions at the health working group in Tokyo recently.

Lord O'Neill of Gatley  
House of Lords

Finally, we were delighted to announce Dame Sally Davies as the UK's future special envoy on AMR in June. By retaining Dame Sally's world-leading expertise on AMR, we will continue to ensure that AMR remains high on the international political agenda, particularly on the areas of global governance and the antimicrobial product development pipeline.

I hope this reply is helpful and that you are assured that the Government is committed to finding practical solutions to this intractable issue.

I will also place a copy of this letter in the House library.

A handwritten signature in black ink, appearing to read 'L. Young', with a large, stylized flourish extending to the right.

**LORD YOUNG OF COOKHAM**